Loading…
← CockpitCompetitor Analysis › ABBOTINDIA.NS Abbott IndiaOpen in the cockpit ↗

Abbott IndiaABBOTINDIA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian listed subsidiary of Abbott selling branded generic medicines and nutrition products, made mainly for the domestic market.

≈ Abbott Laboratories' majority-owned India-listed unitMomentum neutral 40
Mkt cap
$5.80B
US dollars, full cap
Free float
24%
of shares outstanding
$/day
$2.44M
20-day average traded
Fwd P/E
31.1×
forward earnings
ROIC−WACC
+42.5 pp
WACC 9.4%
Hurdle
-2 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · INR₹25,470
1D-1.3%
1W-2.5%
1M-1.7%
3M-4.2%
6M-8.4%
YTD-12.2%
1Y-13.9%
ATR %2.5%
Beta0.21
52w lowhigh16.9% off high

What Abbott India does

Indian listed subsidiary of Abbott selling branded generic medicines and nutrition products, made mainly for the domestic market.

Earns from prescription brands that doctors recommend and patients buy again and again from pharmacies through stockists, with chronic therapies such as thyroid and stomach treatments giving steady refills. A sales force calling on doctors, not advertising, drives volume. Abbott Laboratories of the US holds the majority and supplies new products from its global range.

In one line: Abbott Laboratories' majority-owned India-listed unit.

Products and services

  • Branded prescription formulations (Thyronorm, Digene)
  • Nutrition products
  • OTC brands

Customers

  • Indian retail pharmacies
  • Doctors/hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded generics + nutrition (India)
  • Domestic distribution

What could go right

  • India's growing chronic-disease drug market
  • New product introductions from parent

What could go wrong

  • Price controls (NPPA)
  • Limited pipeline of its own

Moat: narrow (brand, distribution). Long-standing trusted brands (Thyronorm, Digene) with entrenched doctor prescribing habits.

Headquarters: Mumbai, India · Founded: 1944 · Employees: 3,749

Named competitors

Abbott India at a glance

Size Abbott India (ABBOTINDIA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.80B, the 195th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹25,470 on 18 Nov 2026.

Performance Over six months the shares fell 8.4%, against -4.6% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue grew 7.2% over the last twelve months (peer median +13.4%); the operating margin is 27.7% (peer median 20.3%).

Valuation It trades at 31.1× forward earnings against a peer median of 20.4× (4th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 42.5 points above its cost of capital (9.4% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026ABBOTINDIA.NS 93Peer median 92
Six months, rebased to 100: Abbott India against the median of its 20 peers (local-currency closes).

Abbott India financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹72.0B₹69.3B₹64.1B₹58.5B₹53.5B
Revenue growth—+8%+10%+9%—
Gross profit₹27.0B₹24.7B₹22.2B₹19.5B₹17.1B
EBITDA₹20.7B₹19.4B₹17.2B₹14.8B₹12.3B
Net income₹16.5B₹15.5B₹14.1B₹12.0B₹9.49B
Free cash flown/a₹16.6B₹10.8B₹13.1B₹9.61B
Capital expendituren/a₹409M₹526M₹483M₹341M
Total debt₹1.54B₹1.72B₹1.97B₹832M₹1.13B

Quarterly statements and history in the cockpit →

Abbott India competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-25%0%+25%+50%GLANDLGNDSUPN603087MIRM9995BIOCON4506688578BLTE0126Z0ORKALQDA326030PTCTALKEMABBOTINDIA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Abbott India is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×60×GLANDLGNDSUPN6030879995BIOCON4506688578APTXLQDAPTCTABBOTINDIA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Abbott India is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%GLANDLGNDSUPN9995688578APTXLQDA326030ABBOTINDIA.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Abbott India is the large dot.

Abbott India competitors and peer comparison

Head to head with its named competitors (ABBOTINDIA.NS vs SUNPHARMA.NS vs CIPLA.NS vs PFIZER.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Abbott India ABBOTINDIA.NS$5.80B-8%+7%28%31.1×8.0%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Pfizer PFIZER.NS$1.88B-20%+12%34%21.9×11.2%
GlaxoSmithKline Pharmaceuticals GLAXO.NS$4.79B+10%+12%33%37.3×26.4%

How Abbott India compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Abbott India against its 20 peers (data as of 18 Nov 2026)
MeasureABBOTINDIA.NSPeer medianRank in peer set
1-month return-1.7%+1.8%9th lowest of 21
6-month return-8.4%-4.6%10th lowest of 20
Distance from 52-week high-16.9%-25.4%6th highest of 21
Revenue growth (TTM)+7.2%+13.4%7th lowest of 17
Operating margin27.7%20.3%7th highest of 18
Forward P/E31.1×20.4×4th most expensive of 17
Growth the price implies (Req g, 7 yrs)8.0%1.7%4th most demanding of 14
Growth delivered (Del g)+10.0%+13.9%5th lowest of 14
Hurdle (Req g minus delivered)-2.0 pp-16.1 pp5th most demanding of 14
ROIC minus cost of capital+42.5 pp+2.1 pp2nd highest of 17
EV / EBITDA25.5×16.8×3rd most expensive of 11
Net debt / EBITDA-0.7×0.3×5th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%

Questions

Who are Abbott India's main competitors?
Named competitors: Sun Pharmaceutical (SUNPHARMA.NS), Cipla (CIPLA.NS), Pfizer India (PFIZER.NS), GlaxoSmithKline Pharmaceuticals (GLAXO.NS). The cockpit's measured peer set (industry) also includes Gland Pharma (GLAND.NS), Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN), Gan & Lee Pharmaceuticals (603087.SS), Mirum Pharmaceuticals (MIRM), RemeGen (9995.HK).
Is Abbott India expensive compared with its peers?
On forward p/e it trades at 31.1× against a peer median of 20.4×, 4th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has Abbott India stock performed?
Over six months to 18 Nov 2026 the shares returned -8.4% against -4.6% for the median peer; over one year -13.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.